BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler Sells 3,174 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 3,174 shares of the firm’s stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $261.61, for a total value of $830,350.14. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

John Oyler also recently made the following trade(s):

• On Tuesday, June 17th, John Oyler sold 1,460 shares of BeOne Medicines stock. The shares were sold at an average price of $256.49, for a total value of $374,475.40.
• On Monday, June 16th, John Oyler sold 3,680 shares of BeOne Medicines stock. The stock was sold at an average price of $266.05, for a total value of $979,064.00.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The shares were sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Stock Up 0.1%

Shares of ONC stock opened at $267.13 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $141.31 and a 12 month high of $287.88. The stock has a fifty day simple moving average of $247.22. The company has a market capitalization of $29.28 billion, a price-to-earnings ratio of -71.81 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. On average, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ONC has been the topic of several research analyst reports. Royal Bank Of Canada dropped their target price on shares of BeOne Medicines from $312.00 to $311.00 and set an “outperform” rating on the stock in a report on Thursday, May 8th. JPMorgan Chase & Co. raised their price objective on shares of BeOne Medicines from $311.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, April 21st. Guggenheim boosted their price objective on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Bank of America raised shares of BeOne Medicines from a “neutral” rating to a “buy” rating and upped their target price for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, Wall Street Zen raised BeOne Medicines from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, BeOne Medicines has a consensus rating of “Buy” and a consensus price target of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.